Physician profile
Jonathan Hanson
NPI 1689101511
$1,268.51
in general payments reported to CMS, 2019-2025
16 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.89 · 2021: $428 · 2022: $423 · 2023: $88.38 · 2024: $33.78 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $279.19 | 2021-2022 | |
| Abiomed | $243.40 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $120.13 | 2021-2023 | |
| Medtronic, INC. | $115.36 | 2021-2025 | Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $96.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.54 | 2020-2025 | Lifevest |
| Heartflow, INC. | $82.67 | 2025 | |
| Pfizer INC. | $58.98 | 2021-2025 | |
| Asahi Intecc USA, INC. | $29.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.04 | 2020-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $27.05 | 2025 | Onpattro |
| Amgen INC. | $23.76 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2023 | Camzyos |
| Inari Medical, INC. | $21.23 | 2021 | |
| Ucb, INC. | $18.45 | 2024 | Fintepla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.